

1 CUSHING'S SYNDROME IN THE ELDERLY: DATA FROM THE EUROPEAN
2 REGISTRY ON CUSHING'S SYNDROME

3 **Vincent Amodru^{1,3}, Amandine Ferriere², Antoine Tabarin², Frederic Castinetti³,**
4 **Stylios Tsagarakis⁴, Miklos Toth⁵, Richard A Felders⁶, Susan M Webb¹, Martin**
5 **Reincke⁷, Romana Netea-Maier⁸, Darko Kastelan⁹, Atanaska Elenkova¹⁰, Dominique**
6 **Maiter¹¹, Oskar Ragnarsson¹², Alicia Santos¹, Elena Valassi^{13,14,15}**

7
8 ¹IIB-Sant Pau and Department of Endocrinology, Hospital Sant Pau, Dept Medicine, UAB,
9 and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad
10 747), ISCIII, Barcelona, Spain.

11 ²Department of Endocrinology, Diabetes and Nutrition, University of Bordeaux, Bordeaux,
12 France.

13 ³Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale
14 INSERM U1251, Marseille Medical Genetics, Marseille, France and Assistance Publique
15 Hôpitaux de Marseille (APHM), Hôpital de la Conception, Marseille, France.

16 ⁴Evangelismos Hospital, Athens, Greece.

17 ⁵ Department of Internal Medicine and Oncology, Semmelweis University, Budapest,
18 Hungary.

19 ⁶Erasmus University Medical Centre, Rotterdam, The Netherlands.

1 ⁷ Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität
2 München, Ludwig-Maximilians-Universität München, Munich, Germany.

3 ⁸ Department of Internal Medicine, division of Endocrinology, Radboud University Medical
4 Center, Nijmegen, The Netherlands.

5 ⁹ Department of Endocrinology, University Hospital Zagreb, Zagreb, Croatia.

6 ¹⁰ Department of endocrinology, Medical University of Sofia, Sofia, Bulgaria.

7 ¹¹ UCL Cliniques Universitaires St Luc, Brussels, Belgium.

8 ¹² Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden;

9 ¹³ Endocrinology and Nutrition Department, Germans Trias i Pujol Hospital and Research
10 Institute, Badalona, Spain; ¹⁴ Centro de Investigación Biomédica en Red de Enfermedades
11 Raras (CIBERER); ¹⁵ Universitat Internacional de Catalunya (UIC), Barcelona, Spain

12 **ERCUSYN Study Group:** C Amaral, Centro Hospitalar do Porto-Hospital Santo António,
13 Porto, Portugal; A Ambrogio, Istituto Auxologico Italiano IRCCS, University of Milan, Italy;
14 G Aranda, Department of Endocrinology, Hospital Clinic Barcelona, IDIBAPS, UB,
15 Barcelona, Spain; M Arosio, Unit of Endocrine Diseases & Diabetology and Department of
16 Clinical Sciences and Community Health, University of Milan, Milan, Italy; M Balomenaki,
17 Evangelismos Hospital, Athens, Greece; C Berr-Kirmair, Medizinische Klinik und Poliklinik
18 IV, Campus Innestadt, Klinikum der Universität München, München, Germany; J Bertherat,
19 Hôpital Cochin, Paris, France; M. Bolanowski, Wroclaw Medical University, Wroclaw,
20 Poland; J Bollerslev, Section of Specialized Endocrinology, Oslo University Hospital, and
21 Faculty of Medicine, University in Oslo, Oslo, Norway; Brue Thierry, Association pour le
22 Développement des Recherches Biologiques et Médicales; H Cardoso, Centro Hospitalar do

1 Porto-Hospital Santo António, Porto, Portugal; D Carvalho, Hospital de San Joao, Porto,
2 Portugal; F Cavagnini, Istituto Auxologico Italiano IRCCS, Milan, Italy; P Ceccato,
3 Endocrinology Unit, University-Hospital of Padova, Padova, Italy; O Chabre, Hospitalier
4 Universitaire, Grenoble, France; P Chanson, Univ Paris-Sud, Université Paris-Saclay UMR-
5 S1185, Le Kremlin Bicêtre, Paris, France, Assistance Publique-Hôpitaux de Paris, Hôpital
6 de Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Le Kremlin
7 Bicêtre, Paris, France; E Christ, University Hospital of Bern, Inelspital, Division of
8 Endocrinology, Diabetology and Clinical Nutrition, Bern, Switzerland; F Demtröder
9 Zentrum für Endokrinologie, Diabetologie, Rheumatologie Dr Demtröder & Kollegen im
10 MVZ Dr. Eberhard & Partner und Klinikum Dortmund, Germany; J Denes, Division of
11 Endocrinology, 2nd Department of Medicine, State Health Center, Budapest, Hungary; T
12 Deutschbein, Medicover Oldenburg MVZ, Oldenburg, Germany; C Dimopoulou, Max-
13 Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Munich, Germany; A Dreval,
14 Moscow Regional Research Clinical Institute n.a. Vladimirsky, Moscow, Russia; M Droste,
15 Praxis für Endokrinologie Droste, Oldenburg, Germany; JS Duarte, Serviço Endocrinologia
16 CHLO, Hospital Egas Moniz, Lisboa, Portugal; T Dusek, Department of Endocrinology,
17 University Hospital Zagreb, School of Medicine University of Zagreb, Kispaticeva 12, 10000
18 Zagreb, Croatia; E Ertürk, Uludag University School of Medicine, Bursa, Turkey; J A Evang,
19 Section of Specialized Endocrinology, Oslo University Hospital, and Faculty of Medicine,
20 Oslo University in Oslo, Oslo, Norway; C Fajardo, Hospital Universitario de la Ribera,
21 Alzira, Spain; J Fazel, Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum
22 der Universität München, München, Germany; RA Feelders, Erasmus University Medical
23 Centre, Rotterdam, The Netherlands; S Fica, Elias Hospital, Bucharest, Romania; R García-
24 Centeno, Hospital General Universitario Gregorio Marañón, Madrid, Spain; E Ghigo,

1 Molinette Hospital, Department of Internal Medicine, Turin, Italy; M Goth, Division of
2 Endocrinology, 2nd Department of Medicine, State Health Center, Budapest, Hungary; M
3 Godlewska, Department of Endocrinology, Jagiellonian University, Medical College,
4 Krakow, Poland; Y Greenman, Institute of Endocrinology, Metabolism and hypertension, Tel
5 Aviv, Israel; I Halperin, Department of Endocrinology, Hospital Clinic Barcelona, IDIBAPS,
6 UB, Barcelona, Spain; FA Hanzu, Department of Endocrinology, Hospital Clinic Barcelona,
7 IDIBAPS, UB, Barcelona, Spain; A Hermus, Radboud University Medical Center, Nijmegen
8 The Netherlands; G Johannsson, Goteborg University, Goteborg, Sweden; E Hubina,
9 Division of Endocrinology, 2nd Department of Medicine, State Health Center, Budapest,
10 Hungary; A Januszewska, Department of Endocrinology, Jagiellonian University, Medical
11 College, Krakow, P Kamenicky, Univ Paris-Sud, Université Paris-Saclay UMR-S1185, Le
12 Kremlin Bicêtre, Paris F-94276, France, Assistance Publique-Hôpitaux de Paris, Hôpital de
13 Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bicêtre,
14 Paris, F-94275, Institut National de la Santé et de la Recherche Médicale U1185, Le Kremlin
15 Bicêtre, Paris F-94276, France; A Kasperlik-Zaluska, Centre for Postgraduate Medical
16 Education, Warsaw, Poland; J Kirchner, Division of Clinical Endocrinology, Department of
17 Medicine CCM, Charité-Universitätsmedizin, Berlin, Germany; D Kastelan, Department of
18 Endocrinology, University Hospital Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia; I
19 Komerduš, Moscow Regional Research Clinical Institute n.a. Vladimirsky, Moscow, Russia;
20 I Kraljević, Department of Endocrinology, University Hospital Zagreb, Kispaticeva 12,
21 10000 Zagreb, Croatia; M Krsek, 2nd Department of Medicine 3rd Faculty of Medicine,
22 Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic;
23 A Kruszynska, Centre for Postgraduate Medical Education, Warsaw, , Albacete, Spain; C
24 Lamas, Complejo Hospitalario Universitario de Albacete; I Lambrescu, Elias Hospital,

1 Bucharest, Romania; S Lang, Max-Planck-Gesellschaft zur Forderung der Wissenschaften
2 e.V., Munich, Germany; A Luger, Medizinische Universität Wien, Wien, Austria; D Maiter,
3 UCL Cliniques Universitaires St Luc, Brussels, Belgium; N Marpole, Christie Hospital, NHS
4 Trust, Manchester, UK; S Martin, Elias Hospital, Bucharest, Romania; M Martinie, Service
5 d'Endocrinologie-Diabétologie-Nutrition, Grenoble Cedex, France; MJ Martins Oliveira,
6 Centro Hospitalar Vila Nova Gaia /Espinho; O Moros, Zentrum für Endokrinologie,
7 Diabetologie, Rheumatologie Dr Demtröder & Kollegen im MVZ Dr. Eberhard & Partner
8 und Klinikum Dortmund; R Netea-Maier, Radboud University Nijmegen Medical Centre,
9 Nijmegen, The Netherlands; J Newell-Price, The University of Sheffield, Sheffield, UK; M
10 Orbetzova, Clinic of Endocrinology and Metabolic Diseases, "Sv.Georgy" University
11 Hospital, Medical University, Plovdiv, Bulgaria; I Paiva, Hospitais da Universidade de
12 Coimbra; F Pecori Giraldi, Istituto Auxologico Italiano IRCCS, University of Milan, Italy;
13 JC Percovich, Hospital General Universitario Gregorio Marañón; AM Pereira, Leiden
14 University Medical Center, Leiden, The Netherlands; M Pfeifer, Klinični Center, Ljubljana,
15 Slovenia; J Pickel, Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.,
16 Munich, Germany; V Pirags, Pauls Stradiņš Clinical University Hospital, University of
17 Latvia, Riga, Latvia; O Ragnarsson, Goteborg University, Goteborg, Sweden; AD Reghina,
18 Elias Hospital, Bucharest, Romania; M Reincke, Medizinische Klinik und Poliklinik IV,
19 Campus Innenstadt, Klinikum der Universität München, Ludwig-Maximilians-Universität
20 München, Munich, Germany; P Riesgo, Neurosurgery Department, Hospital Universitario
21 de la Ribera, Alzira, Spain; M Roberts, Christie Hospital, NHS Trust, Manchester, UK; S
22 Roerink, Radboud University Medical Center, Nijmegen The Netherlands; O Roig, IIB-Sant
23 Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de
24 Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII;

1 C Rowan, Christie Hospital, NHS Trust, Manchester, UK; P Rudenko, Estonian Endocrine
2 Society, Tallinn, Estonia; MA Sahnoun, Aix-Marseille Université, CNRS, CRN2M UMR
3 7286, 13344 cedex 15, Marseille, and APHM, Hôpital Conception, Marseille, France; J
4 Salvador, University of Navarra, Pamplona, Spain; A Santos, IIB-Sant Pau, Department of
5 Endocrinology/Medicine, Hospital Sant Pau, UAB, Centro de Investigación Biomédica en
6 Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain; C Scaroni,
7 Endocrinology Unit, University-Hospital of Padova; HA Sigurjonsdottir, Landspítali
8 University Hospital, Reykjavik, Iceland and Faculty of Medicine, University of Iceland,
9 Reykjavik, Iceland; T Skoric Polovina, Department of Endocrinology, University Hospital
10 Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia; R Smith, Oxford Radcliffe Hospitals NHS
11 Trust, Oxford, UK; B Stachowska, Department of Endocrinology, Diabetology and Isotope
12 Therapy Wroclaw Medical University, Wroclaw, Poland; G Stalla, Max-Planck-
13 Gesellschaft zur Forderung der Wissenschaften e.V., Munich, Germany; C Strasburger,
14 Division of Clinical Endocrinology, Department of Medicine CCM, Charité-
15 Universitätsmedizin, Berlin, Germany ; A Tabarin, Department of Endocrinology, Diabetes
16 and Nutrition, University of Bordeaux, Bordeaux, France; M Terzolo, Internal Medicine –
17 Endocrinology, San Luigi Hospital; J Tóke, 2nd Departement of Medicine, Semmelweis
18 University, Budapest, Hungary; M Tóth, 2nd Department of Medicine, Semmelweis
19 University, Budapest, Hungary; P Touraine, GH Pitie Salpetriere - Dep. of endocrinology
20 and repr. med.; PJ Trainer, Department of Endocrinology, Christie Hospital, Manchester,
21 UK; S Tsagarakis, Athens Polyclinic General Hospital & Evangelismos Hospital, Athens,
22 Greece; E Valassi, IIB-Sant Pau, Department of Endocrinology/Medicine, Hospital Sant Pau,
23 UAB, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER,
24 Unidad 747), ISCIII, Barcelona, Spain, Universitat Internacional de Catalunya (UIC); G Vila,

1 Medizinische Universität Wien, Wien, Austria; S Vinay, Christie Hospital, NHS Trust,
2 Manchester, UK; M Wagenmakers, Radboud University Medical Center, Nijmegen The
3 Netherlands; S Webb, IIB-Sant Pau, Department of Endocrinology/Medicine, Hospital Sant
4 Pau, UAB, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER,
5 Unidad 747), ISCIII, Barcelona, Spain; S Werner, Praxis für Endokrinologie Droste,
6 Oldenburg, Germany; J Young, Univ Paris-Sud, Université Paris-Saclay UMR-S1185, Le
7 Kremlin Bicêtre, Paris F-94276, France, Assistance Publique-Hôpitaux de Paris, Hôpital de
8 Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bicêtre,
9 Paris, F-94275, Institut National de la Santé et de la Recherche Médicale U1185, Le Kremlin
10 Bicêtre, Paris F-94276, France; P Zdunowski, Centre for Postgraduate Medical Education,
11 Warsaw, Poland; S Zacharieva, Medical University of Sofia, Sofia, Bulgaria ; K Zopf,
12 Division of Clinical Endocrinology, Department of Medicine CCM, Charité-
13 Universitätsmedizin, Berlin, Germany; S Zopp, Medizinische Klinik und Poliklinik IV,
14 Campus Innestadt, Klinikum der Universität München, München, Germany; I Zosin,
15 Romanian Society for Endocrinology, Timisoara, Romania.

16
17 **Corresponding author:**

18 Elena Valassi, MD, PhD

19 Germans Trias i Pujol Hospital and Research Institute

20 Carretera de Canyet, s/n,

21 08916 Badalona, Barcelona (Spain)

22 evalassi@igtp.cat

1

2 **Running head:** Aging in Cushing's syndrome

3

4 **Key words:** Cushing's syndrome; Cushing's disease; aging; Ercusyn; elderly patients

5 **Word count:** 4600

6 **ABSTRACT**

7 **Objective:** To evaluate whether age-related differences exist in clinical characteristics,
8 diagnostic approach and management strategies in patients with Cushing's syndrome
9 included in the European Registry on Cushing's Syndrome (ERCUSYN).

10 **Design:** Cohort study.

11 **Methods:** We analyzed 1791 patients with CS, of whom 1234 (69%) had pituitary-dependent
12 CS (PIT-CS), 450 (25%) adrenal-dependent CS (ADR-CS) and 107 (6%) had an ectopic
13 source (ECT-CS). According to the WHO criteria, 1616 patients (90.2%) were classified as
14 younger (<65 years) and 175 (9.8%) as older (≥ 65 years).

15 **Results:**

16 Older patients were more frequently males and had a lower BMI and waist circumference as
17 compared with the younger. Older patients also had a lower prevalence of skin alterations,
18 depression, hair loss, hirsutism and reduced libido, but a higher prevalence of muscle
19 weakness, diabetes, hypertension, cardiovascular disease, venous thromboembolism and
20 bone fractures than younger patients, regardless of sex ($p < 0.01$ for all comparisons).
21 Measurement of UFC supported the diagnosis of CS less frequently in older patients as

1 compared with the younger ($p<0.05$). An extra-sellar macroadenoma
2 (macrocorticotropinoma with extrasellar extension) was more common in older PIT-CS
3 patients than in the younger ($p<0.01$). Older PIT-CS patients more frequently received
4 cortisol-lowering medications and radiotherapy as a first-line treatment, whereas surgery was
5 the preferred approach in the younger ($p<0.01$ for all comparisons). When transsphenoidal
6 surgery was performed, the remission rate was lower in the elderly as compared with their
7 younger counterpart ($p<0.05$).

8 **Conclusions:**

9 Older CS patients lack several typical symptoms of hypercortisolism, present with more
10 comorbidities regardless of sex, and are more often conservatively treated.

11

12 **SIGNIFICANCE STATEMENT**

13 Clinical presentation of Cushing's syndrome (CS) was different in older patients as compared
14 with that in the younger, with the former lacking some of the typical features of cortisol
15 excess while presenting with a greater burden of comorbidities and an elevated prevalence
16 of muscle weakness. Levels of urinary free cortisol were often within the normal range in the
17 elderly, and a conservative treatment was frequently chosen in them. Our data emphasize the
18 need of maintaining a high clinical suspicion of hypercortisolism in the general population,
19 while taking into account specific age-related differences in the presentation of symptoms.

20 Our data may contribute to reduce the delay to diagnosis in CS, which has been associated
21 with increased morbidity and mortality.

22

1 INTRODUCTION

2 Cushing's syndrome (CS) is usually caused by excessive ACTH release from a pituitary
3 corticotrope adenoma (Cushing's disease, CD) and, less frequently, by ectopic ACTH or
4 (very rarely) CRH production. CS can also be ACTH-independent when caused by cortisol-
5 secreting adrenocortical tumors or hyperplasia (1). CS is most frequently diagnosed in
6 women (female to male ratio, 3-5:1) aged 40-50 years and is associated with a constellation
7 of symptoms and signs, including, among others, weight gain, centripetal fat deposition,
8 purple striae, skin thinning, muscle wasting and fatigue. Hypercortisolism is also related to
9 several comorbidities, such as type 2 diabetes mellitus, arterial hypertension, cardiovascular
10 disease, venous thromboembolism, mood disorders and osteoporosis which result in poor
11 quality of life (QoL) and elevated mortality (2, 3, 4).

12 Life expectancy has increased during the last decades and the general population is
13 progressively growing older, especially in Western countries (5). Consequently, the number
14 of elderly people with endocrine diseases rising and mean age of patients regularly followed
15 in referral centers for low-prevalence diseases, such as CS, is older than in the past.

16 Advanced age at diagnosis of CS is associated with an elevated mortality, both
17 perioperatively and following long-term after remission (6, 7). Moreover, data from the
18 European registry on Cushing's Syndrome (ERCUSYN) showed that older age at diagnosis
19 predicted worse self-reported QoL more than one year after treatment (8).

20 Data on clinical presentation and management of CS in older patients are scarce. Some
21 authors have reported individual cases of older patients with CS (9, 10, 11, 12) but have not
22 focused on specific age-related differences in clinical presentation. Minniti et al. suggested
23 that the clinical picture of CD in older patients may be milder than in younger patients (13).

1 Conversely, in a recent study, Qiao et al. showed that 45 CD patients older than 60 more
2 commonly presented with a catabolic phenotype and cardiometabolic comorbidities as
3 compared with younger patients (14).

4 Our study aimed to describe the age-related differences in clinical characteristics, diagnostic
5 approach, management strategies, treatment outcome and mortality in patients with CS
6 included in the European Registry on Cushing's Syndrome (ERCUSYN) the largest database
7 existing to date on this condition.

8

9 **METHODS**

10 **Description of the database**

11 ERCUSYN is a web-based, multicenter, observational study that enrolled 1972 patients from
12 57 centers in 26 European countries at the time of the study (between January 1st, 2000 and
13 January 31st, 2021). Patients were classified into four major etiologic groups: pituitary-
14 dependent CS (PIT-CS), adrenal-dependent CS (ADR-CS; adrenal adenoma), CS from
15 ectopic source (ECT-CS) and CS from other etiologies (OTH-CS), mainly including cyclic
16 hypercortisolism. Etiologic classification was based on histologic documentation of ACTH-
17 secreting or adrenal tumors. In case histological reports were not available, expert centers
18 involved confirmed diagnosis in their local multidisciplinary team meetings, based on
19 biochemical and clinical resolution of hypercortisolism after surgical resection, or, in patients
20 who were not operated on, based on biochemical test results and/or imaging.

21 A detailed description of the database layout has been provided elsewhere (7). Briefly, the
22 "diagnosis" section contains information at diagnosis: baseline demographics and
23 anthropometric characteristics, etiology of CS and diagnosis date, delay between onset of

1 symptoms and final diagnosis of CS, clinical features, concomitant pituitary hormone
2 deficiencies, menopausal status, comorbidities, such as cardiovascular disease (defined as a
3 history of coronary heart disease or cerebrovascular accidents) and quality of life (QoL), the
4 latter being assessed using both the generic EuroQoL and the disease-generated CushingQoL
5 questionnaires. In this study, only EuroQoL measures will be shown, due to the low number
6 of CushingQoL questionnaires administered to older people across Europe. The “imaging”
7 subsection contains information on pituitary MRI (“microadenoma”, “extrasellar
8 macroadenoma”, “intrasellar macroadenoma”, and “no visible adenoma”). The “treatment”
9 section contains information on surgery (type, date, number), RT (type, date), and medical
10 treatment (date, dose, duration, number). The “follow-up” section resembles the layout of the
11 “Diagnosis” section and contains information on clinical and hormonal status, including
12 concomitant pituitary hormone deficiencies and menopausal status on each follow-up visit.
13 The “death” section comprises information on the age of the deceased patients and the cause
14 of death. Diagnosis of autonomous cortisol secretion and adrenal carcinoma were exclusion
15 criteria of the ERCUSYN database.

16 Patients were grouped depending on their age at the time of diagnosis. Patients aged ≥ 65
17 were considered “elderly” and were compared with “younger” patients, aged <65 years. This
18 classification was in accordance with the WHO definition (15). Data on MRI findings and
19 remission rate in PIT-CS patients were also stratified, in women, based on the estrogen status
20 and menopausal status. In particular, estrogen-sufficient women (premenopausal without
21 gonadotropin deficiency) were compared with postmenopausal women or women with
22 unreplaced gonadotropin deficiency.

1 The ERCUSYN study was approved by the ethics committee of the Hospital Sant Pau,
2 Barcelona, Spain, which is the coordinating centre of the project. In addition, the local ethics
3 committee approval was obtained for each participating institution and all patients gave their
4 informed consent, according to the EU *General Data Protection Regulation (GDPR)*. This
5 research complies with the Declaration Of Helsinki. All the data inserted into the system
6 were carefully monitored for inconsistencies and validated before starting statistical analysis.
7

8 **Statistical analysis**

9 For statistical analysis, GraphPad Prism® version 9 (Graph-Pad Software, San Diego, Calif.,
10 USA) was used. Continuous data are presented as mean \pm SD, while categorical variables are
11 presented as absolute/relative frequencies. We performed statistical comparisons of
12 quantitative data with Student's *t* test or ANOVA. When variables were not normally
13 distributed, we used the Mann-Whitney U test. For statistical comparisons of dichotomous
14 data, we used the χ^2 test and, when the sample size was < 10 we used the exact Fisher test.
15 Comparison of remission rates depending on age were evaluated using Kaplan-Meier
16 analysis and compared using the log-rank test. All statistical tests were two sided with *p*
17 values of < 0.05 considered to be significant.
18

19 **RESULTS**

20 **1- CHARACTERISTICS OF THE OVERALL POPULATION**

21 At the time of the analysis, 1972 patients with CS were included in the database. One hundred
22 and eighty-one patients were excluded because the cause of CS was classified as “not
23 known”, “other” or related to “illicit receptor expression”. Finally, we analyzed 1791 CS

1 patients classified as PIT-CS (n=1234), ADR-CS (n=450) or ECT-CS (n=107). The mean
2 age of the whole population was 44.7±14.1 years and 1397 (78%) were females. One-
3 thousand six hundred and sixteen patients (90.2%) were classified as younger (<65 years)
4 and 175 (9.8%) were classified as elderly patients (≥ 65 years).

5

6 **2- AGE-RELATED DIFFERENCES IN CLINICAL FEATURES AT** 7 **DIAGNOSIS**

8 The clinical presentation at diagnosis, depending on age, is shown in Table 1. There was a
9 female preponderance in younger patients as compared with older [1289 (79.7%) vs. 107
10 (61.1%); p<0.01]. Elderly patients had lower BMI (26.7±5.7kg/m² vs. 29.7±7.1kg/m²;
11 p<0.01), lower waist circumference (97.1±10.8 vs. 103.1±16.5; p<0.01), lower prevalence of
12 weight gain [87 patients (49.7%) vs. 1184 patients (73.2%); p<0.01], higher prevalence of
13 hypertension [156 patients (89.1%) vs. 1084 patients (67.1%); p<0.01] and higher prevalence
14 of diabetes mellitus [84 patients (48%) vs. 446 patients (27.6%); p<0.01], in comparison to
15 younger patients. Elderly patients were less frequently depressed than younger ones [35
16 (20%) vs. 538 (33.3%); p<0.01] and were less frequently followed by a psychiatrist [9 (5.1%)
17 vs. 170 patients (10.5%); p=0.02]. Elderly patients had lower prevalence of skin symptoms
18 [103 patients (58.8%) vs. 1123 (69.4%); p<0.01], hirsutism in females [23 (22%) vs. 668
19 (52%); p<0.01], hair loss in females [22 (21%) vs. 351 (27%); p=0.03], and loss of libido [14
20 (8%) vs. 325 (20.1%); p<0.01] in comparison to younger patients. Prevalence of fractures
21 was higher in the elderly [38 (21.7%) vs. 217 (13.4%); p<0.01] in comparison to younger
22 patients.

23

3- AGE-RELATED DIFFERENCES IN CLINICAL FEATURES OF HYPERCORTISOLISM AT DIAGNOSIS BASED ON THE ETIOLOGY

3a- PIT-CS

Age-related clinical presentation in PIT-CS is shown in Figure 1 and Table 2. Of 1234 PIT-CS patients with data available, 103 patients (8.3%) were older, and 1131 (91.7%) were younger. Fifty-six older and 889 younger patients were females (54% vs. 72%; $p<0.01$). The commonest metabolic features in elderly patients as compared with their younger counterparts were lower BMI, lower waist circumference, lower prevalence of weight gain, higher prevalence of hypertension and higher prevalence of diabetes mellitus ($p<0.01$ for all comparisons). Prevalence of muscle weakness in the older was greater as compared with that in younger patients ($p<0.01$). Concerning psychiatric complications of PIT-CS, elderly patients were less depressed and, accordingly, less frequently followed by a psychiatrist ($p<0.01$ and $p=0.03$ respectively). Older females had lower prevalence of hirsutism and hair loss, while low libido and higher prevalence of fractures were observed in the overall older population as compared with younger ($p<0.01$ for all comparisons).

Data on cardiovascular morbidity were available in all 103 older and 1131 younger patients. Prevalence of cardiovascular disease at diagnosis was higher in the older as compared with the younger ([24/103 (23%) vs. 25/1131 (2%); $p<0.01$]. Ischemic heart disease was more frequently reported in the older as compared with the younger [19/103 (18.4%) vs. 20/1131 (1.5%); $p<0.01$]. Thrombosis was more frequently reported in the older as compared with the younger [26/103 (25.2%) vs. 59/1131 (5.2%); $p<0.01$].

1 **3b- ADR-CS**

2 Age-related clinical presentation in ADR-CS is shown in Table 3.

3 Of 450 ADR-CS patients with available data, 52 (11.6%) were older and 398 (88.4%)
4 younger. Thirty-eight older patients and 352 younger patients were females (73% vs. 88%;
5 $p<0.01$). Prevalence of hypertension and type 2 diabetes was greater in the older as compared
6 with the younger ($p<0.01$ for all comparisons). Older females had lower prevalence of
7 hirsutism and hair loss ($p<0.05$). The differences in the prevalence of other clinical features
8 between the two groups were not statistically significant, most probably due to the small
9 number of patients included.

10 In the younger group, the proportion of women was lower in PIT-CS patients as compared
11 with ADR-CS patients [889 (72%) vs. 352 female patients (88%), respectively; $p=0.04$].
12 Prevalence of hypertension was lower in PIT-CS as compared with ADR-CS [724 (64%) vs.
13 291 (73%); $p<0.01$]. Prevalence of hirsutism was higher in PIT-CS women as compared with
14 ADR-CS women [526 (46%) vs. 116 (29%), respectively; $p<0.01$]. The prevalence of skin
15 symptoms was higher in PIT-CS as compared with ADR-CS patients [818 (72%) vs. 238
16 (60%). The prevalence of weight gain was higher in PIT-CS as compared with ADR-CS
17 patients (904 (80%) vs. 226 (57%). respectively, $p<0.01$].

18 Among elderly patients (>65 years old), the mean waist circumference was lower in PIT-CS
19 as compared with ADR-CS patients (95 cm vs. 103 cm, respectively; $p=0.03$). The mean
20 BMI was lower in PIT-CS as compared with ADR-CS patients (24 Kg/m^2 vs. 30 Kg/m^2 ,
21 respectively; $p=0.01$).

1

2 **3c- ECT-CS**

3 Of 107 ECT-CS patients with data available, 20 (18.7%) were older and 87 (81.3%) were
4 younger patients. Prevalence of hypertension and type 2 diabetes was greater in the older as
5 compared with the younger [18 (90%) vs. 69 (79%) for hypertension and 18 (90%) vs. 33
6 (38%) for type 2 diabetes; $p<0.01$ for both comparisons]. The differences in the prevalence
7 of other clinical features between the two groups were not statistically significant, most
8 probably due to a smaller numbers of patients.

9

10 **4- SEX-RELATED DIFFERENCES IN OLDER PATIENTS AT DIAGNOSIS**

11 Of 175 elderly patients with data available, 68 were males (38.8%) and 107 (61.2%) were
12 females. At diagnosis, female elderly patients had a significantly higher systolic blood
13 pressure as compared with their male counterparts (152 ± 15 mmHg vs. 140 ± 6 ; $p<0.01$) and
14 loss of libido was significantly less prevalent in elderly females in comparison with elderly
15 males [4 (4%) vs. 14 (21%); $p<0.01$] (Table 4). Older males had a significantly lower BMI
16 (26 ± 9 kg/m² vs. 29.6 ± 6 kg/m²; $p=0.02$), higher prevalence of diabetes mellitus [36 (53%) vs.
17 112 (34%); $p<0.01$] and a lower prevalence of depression [9 (19%) vs. 130 (40%); $p<0.01$]
18 as compared with their younger counterpart (Table 4). Older females had a significantly
19 higher prevalence of hypertension [96 (90%) vs. 830 (64%); $p<0.01$], higher prevalence of
20 muscle weakness [63 (59%) vs. 615 (48%); $p=0.01$], higher prevalence of diabetes mellitus
21 [56 (52%) vs. 354 (27%); $p<0.01$], lower prevalence of depression [23 (22%) vs. 408 (32%);
22 $p=0.02$], lower prevalence of weight gain [56 (53%) vs. 1019 (79%); $p<0.01$], and higher
23 prevalence of fractures [26 (24%) vs. 145 (11%); $p=0.01$] (Table 4).

1

2 5- HEALTH-RELATED QUALITY OF LIFE AT DIAGNOSIS

3 Of 437 patients (24.4%) with EuroQoL data available, 34 (7.8%) were older and 403 (92.2%)
4 were younger. Older patients scored worse on several items of EuroQoL as compared with
5 younger patients, including mobility issues and self-care issues but they scored better on
6 anxiety/depression issues ($p < 0.05$ for all comparisons).

7

8 6- AGE-RELATED DIFFERENCES IN DIAGNOSIS AND MANAGEMENT 9 STRATEGIES IN PATIENTS WITH PIT-CS

10 6a- Diagnosis in elderly patients with PIT-CS

11 We also separately analyzed PIT-CS patients, who represented the largest etiologic group in
12 the ERCUSYN database.

13 Hormone assessment

14 Of the 943 patients with biochemical data available, 75 (8%) were older and 868 (92%) were
15 younger. In older patients with PIT-CS, UFC measurements supported the diagnosis of
16 hypercortisolism PIT-CS less frequently than in younger patients [(65/75 (87%) vs. 828/868
17 (95%); $p < 0.01$]. The rest of hormone assessments were similar between younger and older
18 patients with PIT-CS.

19 Imaging

20 We had available information on pituitary MRI in 1113 patients (90%) of whom 1021 were
21 younger (90%) and 92 older (89%). The prevalence of a microadenoma was lower in the

1 older in comparison to the younger [36(39%) vs. 574 (56%); $p<0.01$]. Prevalence of an extra-
2 sellar macroadenoma was higher in older patients in comparison to the younger with PIT-CS
3 [16 (17.4%) vs. 103 (10.1%); $p=0.02$]. Corticotropinomas were not visualized on MRI in 219
4 younger patients (21.5%) vs. 23 older patients (25%); $p=0.4$.

5 Of 1113 patients with pituitary MRI data available, 810 patients were females (72.7%), of
6 whom 563 (69.5%) were estrogen-sufficient/premenopausal and 247 (30.5%) were estrogen-
7 deficient/ postmenopausal. Extrasellar macroadenomas were less prevalent in estrogen
8 sufficient/premenopausal women as compared with estrogen deficient/postmenopausal
9 women [37/563 (6.5%) vs. 39/247 (15.8%); $p<0.01$].

10

11 **6b- Choice of treatment in elderly patients with PIT-CS**

12 Differences in management strategy in patient with PIT-CS, depending on age, are shown in
13 Table 5.

14 Of the 1234 PIT-CS patients with data on first-line treatment available, 1082 (87.7%)
15 underwent pituitary surgery, of whom 71 were older (68.9%) and 1011 younger (89.3%)
16 ($p<0.01$). The rate of older patients who never received transsphenoidal surgery was higher
17 as compared with the younger [32 (31.1%) vs. 120 (10.6%); $p<0.01$].

18 Cortisol-lowering medications were more frequently chosen as a first-line treatment in the
19 older as compared with the younger (41 (39.8%) vs. 307 (27.1%); $p<0.01$).

20 A total of 137 patients with PIT-CS were treated with radiotherapy (RT), of whom 120
21 younger (10.6%) and 17 older (13.6%) ($p=0.06$). Use of radiotherapy as a first line therapy

1 was more frequent in elderly patients as compared with younger patients (6 (35.3%) vs. 8
2 (6.6%); $p<0.01$).

3 The prevalence of an extrasellar adenoma was greater in patients who were conservatively
4 treated with first-line medical therapy as compared with that in the group of patients who
5 underwent first-line surgery [13/41 (31%) vs. 3/71 (4%), respectively; $p<0.001$].

6 Thirty-eight (37%) older patients were diagnosed before 2010 and 65 (63%) after 2010. We
7 did not find any differences in the frequency of any modalities of first-line treatment in
8 patients who received diagnosis of CD before 2010 as compared with those diagnosed after
9 2010 ($p=0.8$ for TSS; $p=0.7$ for both radiotherapy and medical treatment). However, more
10 CD patients with persistent/recurrent disease included after 2010 received medical therapy
11 as compared with those included before 2010 [52/65 (80%) vs. (12/37) (32%), respectively;
12 $p<0.01$].

14 **6c- Age-related differences in remission and relapse rate in PIT-CS patients**

15 Of 1047 patients with PIT-CS who underwent transsphenoidal surgery with data available,
16 71 (6.8%) were older and 976 (93.2%) were younger. Remission rate was lower in the older
17 as compared with the younger [37 (52%) vs. 636 (65%); $p=0.03$]. Relapse rates after
18 successful pituitary surgery were not different in the older as compared with the younger
19 ($p=0.8$). In elderly patients, remission rates were 48%, 51%, 51% and 51% at 1 year, 5 years,
20 10 years and 15 years respectively vs. 60%, 65.5%, 66.3% and 66.3% at 1 year, 5 years, 10
21 years and 15 years respectively in younger patients ($p=0.04$) (Figure 2).

1 When only female patients without gonadotropin deficiency were analyzed and stratified
2 according to their reproductive status, estrogen-sufficient/premenopausal patients had higher
3 remission rate after the first transsphenoidal surgery as compared with that in estrogen
4 deficient/postmenopausal women [358/586 (61%) vs. 142/291 (48%); $p < 0.01$]. Relapse rate
5 was also higher in estrogen-sufficient as compared with that in estrogen-deficient patients
6 [73/358 (20%) vs. 18/142 (12%); $p = 0.04$].

7

8 7- AGE-RELATED DIFFERENCES IN MORTALITY

9 Among the 1791 patients included in the study, 67 (3.7%) died during the follow-up period.
10 As expected, a larger proportion of older patients had died at last follow-up as compared with
11 the younger [21/175 (12%) vs. 46/1616 (3%); $p < 0.01$]. The causes of death were the
12 following: tumor progression ($n = 21$; 31.3%), infections ($n = 12$; 17.9%), cardiovascular
13 disease ($n = 5$; 7.5%), cerebrovascular disease ($n = 5$; 7.5%), thromboembolism ($n = 2$; 3%) or
14 other causes ($n = 12$; 17.9%). There were no age-related differences in the causes of death.
15 Active disease predicted mortality in the elderly [HR, 3.3 (95% CI, 1.2-8.4)].

16 In patients with PIT-CS and ADR-CS, proportion of older patients who died was higher than
17 that of the younger [14/103 (13%) vs. 22/1131 (2%); $p < 0.01$ for PIT-CS; 3/52 (6%) vs. 4/398
18 (1%); $p = 0.04$ for ADR-CS). In patients with ECT-CS, there were no age-related differences
19 in mortality rate between the groups.

20 Of 67 deceased patients, 29 (43.2%) died within 90 days from start of treatment. The
21 proportion of elderly who died within 90 days from treatment did not differ from the
22 proportion in younger patients [11/21 (52.4%) vs. 18/46 (39.1%); $p = 0.3$].

1

2 **DISCUSSION**

3 Our data from ERCUSYN demonstrated that the proportion of CS in patients older than 65
4 years was 9.8%, and there were age-specific differences in the clinical presentation of
5 endogenous hypercortisolism. Several typical symptoms of hypercortisolism were less
6 frequent in the older patients as compared with the younger, including weight gain, skin
7 alterations, hair loss, hirsutism, low libido and depression. On the contrary, the prevalence
8 of muscle weakness, hypertension, type 2 diabetes, cardiovascular disease,
9 thromboembolism and bone fractures was higher in the elderly. In the second part we only
10 analyzed PIT-CS patients because they represented the largest etiologic group which
11 provided the most significant results. Indeed, focusing on PIT-CS, older patients often had a
12 macroadenoma but less frequently underwent transsphenoidal surgery (TSS) as compared
13 with the younger. Instead, cortisol-lowering agents and radiotherapy were more often chosen
14 as a first-line therapeutic options in the former.

15 Our data also showed that aging attenuates the well-known female preponderance in the
16 prevalence of PIT-CS observed in adult population (14, 16). In fact, slightly more than half
17 of the elderly patients were females, whereas women represented almost three-quarters of
18 the younger patients. Because estrogens enhance corticotrope proliferation *in vitro*, and the
19 expression of the estrogen receptor beta (ER β) has been detected in the majority of ACTH-
20 secreting adenomas, the reduction of the “gender-gap” we have found in aged patients with
21 PIT-CS may be due to the lack of estrogens in older women, and resembles that reported in
22 childhood (17, 18, 19). Accordingly, we have shown that estrogen-sufficient women with
23 PIT-CS presented with a higher relapse rate after the first TSS as compared with

1 postmenopausal patients, suggesting that corticotropinomas may have a more aggressive
2 biological behavior in the former. However, remission rate was also greater in estrogen-
3 sufficient women as compared with their estrogen-deficient counterparts, likely due to the
4 fact that the former more frequently had a microadenoma as compared with the latter. In fact,
5 older PIT-CS patients of both sexes more commonly had a macroadenoma and less frequently
6 experienced remission after TSS as compared with the younger population. These data are
7 novel and in contrast with those by Qiao et al. who showed a tendency towards a lower female
8 to male ratio in the older as compared with the younger, but did not document any age-related
9 differences in both the adenoma size at diagnosis and the remission rate after surgery in 45
10 patients older than 60, as compared with 90 younger patients (14).

11 Higher prevalence of an extrasellar macroadenoma in our larger population of elderly
12 patients is an interesting finding. Although the time elapsed from the appearance of
13 symptoms to diagnosis, as reported by the patients, was similar between the older and the
14 younger population, a certain delay in the recognition of symptoms and consequent later
15 detection of the underlying pituitary lesion in this group of patients cannot be excluded. This
16 is in accordance with our results demonstrating that “red-flag symptoms” of CS, such as
17 facial plethora, purple striae, easy bruising and central obesity, are often lacking in older
18 patients, making the early diagnosis of hypercortisolism more difficult in them than in the
19 younger. Even the appearance of less specific symptoms of CS, such as weight gain, was not
20 as frequent in the older as it was in the younger, further contributing to reduce the probability
21 that an aged patient seeks medical advice to treat or prevent them. Furthermore, it is intuitive
22 that some of the most frequently reported symptoms or comorbidities in the elderly, such as
23 muscle weakness, hypertension, type 2 diabetes and bone fractures, might have been

1 erroneously attributed to the aging process itself by clinicians, who may overlook other
2 important clinical signs suggestive of cortisol excess and, therefore, exclude *a priori* other
3 diagnoses.

4 Our data emphasize the need of maintaining a high clinical suspicion of hypercortisolism in
5 the general population, while taking into account specific age-related differences in the
6 presentation of symptoms.

7 Surprisingly, we found a lower prevalence of depression in the elderly with PIT-CS in
8 comparison to the younger. Several mechanisms associated with both aging and
9 hypercortisolism contribute to the development of depressive symptoms (20). Indeed,
10 depression was documented in 36% of Ercusyn patients overall, whereas Qiao et al. showed
11 that prevalence of mood disorders was around 29% in both younger and older patients. We
12 showed that depression was diagnosed in 18% of older PIT-CS patients vs. 35% of the
13 younger. A possible explanation for these discrepant results may be that severity of mood
14 disorders may be underestimated in the elderly due to their tendency to underreport
15 depressive symptoms (21). Indeed, affective symptoms in CS patients are often
16 underrecognized by the clinicians, which may lead to an inaccurate estimation of the real
17 prevalence of depression in this condition (22). Moreover, major depression has been
18 demonstrated to occur less frequently in older subjects, thus further complicating the
19 recognition of symptoms (23). Additionally, younger patients perceiving Cushing-related
20 symptoms may be more impacted emotionally due to their physical and psychological
21 limitations, than older patients who would conform more, considering them part of their
22 aging process.

1 We have shown that muscle weakness and myopathy were more common in older patients
2 as compared with the younger, whereas the latter more frequently presented with central
3 obesity, hirsutism/hair loss and skin alterations including easy bruising, purple striae and thin
4 skin. Of note, a physiological skin thinning usually occurs with aging and, therefore, it may
5 be underestimated as a potential manifestation of cortisol excess during physical
6 examination. On the contrary, Qiao et al. reported more central obesity in the elderly along
7 with more muscle wasting and did not find any age-related differences in the prevalence of
8 other typical signs and symptoms of hypercortisolism, such as fatigue and skin abnormalities
9 (14). Both cortisol excess and aging are known to cause sarcopenia, defined as low muscle
10 mass, impaired muscle quality and poor functionality (24, 25). While both conditions may
11 have concurred to increase the prevalence of muscle weakness observed in our population,
12 there may be age-related differences in the glucocorticoid receptor sensitivity in peripheral
13 tissues, making the elderly more prone to develop muscle impairment, as well as other
14 comorbidities, in the presence of excessive cortisol, as compared with the younger (26, 27,
15 28, 29). While studies in humans are needed to investigate this hypothesis, additional
16 mechanisms for muscle weakness and sarcopenia in CS might be lower sex hormone levels
17 due to cortisol suppression of the hypothalamic-pituitary-gonadal axis and suppression of
18 GH and IGF-1 secretion by excess cortisol, in addition to lower levels of IGF-1 in elderly
19 due to physiological decline by aging.
20 Indeed, the rate of muscle wasting, as well as that of type 2 diabetes and hypertension, was
21 higher in older CS patients as compared with that in patients with non-functioning pituitary
22 adenomas of the same age, suggesting that the negative, multisystemic effect of
23 hypercortisolism could prevail on that caused by aging alone (14). Moreover, a detrimental
24 effect of concomitant low IGF-I levels on muscle health cannot be excluded, although we did

1 not find any differences in the prevalence of GH deficiency between older and younger
2 patients (30). The paradoxical results on the lack libido-related complain in elderly patients
3 with CS may be explained by the fact that elderly patients under-report libido-related issues
4 and physicians probably also under-assess these issues. Indeed, although it is not fully
5 understood, the aging-related decrease in libido correlates with the physiological decrease in
6 sex hormone levels (31).

7 We have also described for the first time that there are differences in the management of PIT-
8 CS between elderly patients and their younger counterparts throughout Europe. Although the
9 surgical resection of the corticotropinoma remains the first-line treatment of PIT-CS, elderly
10 patients were treated in a more conservative manner, undergoing surgery less frequently than
11 the younger whereas receiving more cortisol-lowering drugs and radiotherapy as first line
12 treatments (32). When focusing on patients with micro adenomas, the proportion of patients
13 treated more conservatively remained higher in older patients as compared with their younger
14 counterparts. A more conservative approach relying on medical therapy or radiotherapy
15 instead of surgery may be advisable in the elderly with an elevated comorbidity load, which
16 may increase the risk of death or major postoperative complications. Accordingly, in a recent
17 study focusing on the outcomes of transsphenoidal surgery in 123 elderly patients with
18 pituitary adenomas, Thakur et al. showed that this procedure is effective and safe in carefully
19 selected subjects, being followed by a low complication rate and a postoperative readmission
20 rate of 11%, mostly for delayed hyponatremia (33). As a matter of fact, older patients had
21 more thromboembolism, cardiovascular diseases, hypertension and type 2 diabetes at
22 diagnosis as compared with the younger, which may potentially increase peri- and
23 postoperative morbidity and mortality (7, 34, 35). However, longitudinal studies comparing

1 the long-term efficacy and safety of either approach are needed, especially in view of the
2 growing proportion of elderly patients referred to endocrine units in the recent years.

3 Missing or incomplete information is a potential shortcoming of a multicenter registry like
4 the Ercusyn, but the proportion of patients with complete data was high and allowed creating
5 the largest dataset available to date. The database was also carefully reviewed for data quality
6 prior to data analysis, which guaranteed a satisfactory reliability of our results.

7 Another limitation is the lack of both quantitative data and standardized methods to evaluate
8 hormone levels. Indeed, we have shown that UFC measurements supported the diagnosis of
9 CS in the elderly less frequently than in the younger, suggesting that a milder hormone
10 elevation may develop in the former. This finding may be due to a milder hormone elevation

11 in the former, although a concomitant renal impairment in the elderly may also play a role
12 To establish some hormone cut-offs potentially associated with a more suggestive clinical
13 picture in older patients would be helpful, to develop a diagnostic algorithm for early
14 recognition of hypercortisolism in this category of subjects. Yet, Ercusyn data cannot
15 currently address this point.

16 In conclusion, our study showed that clinical presentation of CS is different in older patients
17 as compared with that in the younger, with the former lacking some of the typical features of
18 cortisol excess while presenting with a greater burden of comorbidities and an elevated
19 prevalence of muscle weakness along with levels of UFC which are often within the normal

20 range. Moreover, although older patients frequently have a macroadenoma at diagnosis, a
21 conservative, non-surgical management is more often chosen likely in the attempt to avoid
22 postoperative complications. Future studies are needed to evaluate the long-term effects of
23 each treatment in the elderly, and establish the safest strategy within an individualized
24 approach.

1 **Declaration of interest**

2 MR received consulting fees from Novartis, Recordati, Crinetics, HRA Pharma and Ipsen
3 during the past 5 years.

4 DK received consulting fees Recordati Rare Disease and HRA Pharma Rare Diseases

5 **Funding**

6 ERCUSYN was set up with funding from the EU (PHP 800200) and been supported by
7 unrestricted grants from Novartis, Ipsen, HRA and the European Society of Endocrinology.

9 **Acknowledgements**

10 **ERCUSYN Study Group:** C Amaral, Centro Hospitalar do Porto-Hospital Santo António,
11 Porto, Portugal; A Ambrogio, Istituto Auxologico Italiano IRCCS, University of Milan, Italy;
12 G Aranda, Department of Endocrinology, Hospital Clinic Barcelona, IDIBAPS, UB,
13 Barcelona, Spain; M Arosio, Unit of Endocrine Diseases & Diabetology and Department of
14 Clinical Sciences and Community Health, University of Milan, Milan, Italy; M Balomenaki,
15 Evangelismos Hospital, Athens, Greece; C Berr-Kirmair, Medizinische Klinik und Poliklinik
16 IV, Campus Innenstadt, Klinikum der Universität München, München, Germany; J Bertherat,
17 Hôpital Cochin, Paris, France; M. Bolanowski, Wroclaw Medical University, Wroclaw,
18 Poland; J Bollerslev, Section of Specialized Endocrinology, Oslo University Hospital, and
19 Faculty of Medicine, University in Oslo, Oslo, Norway; Brue Thierry, Association pour le
20 Développement des Recherches Biologiques et Médicales; H Cardoso, Centro Hospitalar do
21 Porto-Hospital Santo António, Porto, Portugal; D Carvalho, Hospital de San Joao, Porto,

1 Portugal; F Cavagnini, Istituto Auxologico Italiano IRCCS, Milan, Italy; P Ceccato,
2 Endocrinology Unit, University-Hospital of Padova, Padova, Italy; O Chabre, Hospitalier
3 Universitaire, Grenoble, France; P Chanson, Univ Paris-Sud, Université Paris-Saclay UMR-
4 S1185, Le Kremlin Bicêtre, Paris, France, Assistance Publique-Hôpitaux de Paris, Hôpital
5 de Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Le Kremlin
6 Bicêtre, Paris, France; E Christ, University Hospital of Bern, Inelspital, Division of
7 Endocrinology, Diabetology and Clinical Nutrition, Bern, Switzerland; F Demtröder
8 Zentrum für Endokrinologie, Diabetologie, Rheumatologie Dr Demtröder & Kollegen im
9 MVZ Dr. Eberhard & Partner und Klinikum Dortmund, Germany; J Denes, Division of
10 Endocrinology, 2nd Department of Medicine, State Health Center, Budapest, Hungary; T
11 Deutschbein, Medicover Oldenburg MVZ, Oldenburg, Germany; C Dimopoulou, Max-
12 Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Munich, Germany; A Dreval,
13 Moscow Regional Research Clinical Institute n.a. Vladimirsky, Moscow, Russia; M Droste,
14 Praxis für Endokrinologie Droste, Oldenburg, Germany; JS Duarte, Serviço Endocrinologia
15 CHLO, Hospital Egas Moniz, Lisboa, Portugal; T Dusek, Department of Endocrinology,
16 University Hospital Zagreb, School of Medicine University of Zagreb, Kispaticeva 12, 10000
17 Zagreb, Croatia; E Ertürk, Uludag University School of Medicine, Bursa, Turkey; J A Evang,
18 Section of Specialized Endocrinology, Oslo University Hospital, and Faculty of Medicine,
19 Oslo University in Oslo, Oslo, Norway; C Fajardo, Hospital Universitario de la Ribera,
20 Alzira, Spain; J Fazel, Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum
21 der Universität München, München, Germany; RA Feelders, Erasmus University Medical
22 Centre, Rotterdam, The Netherlands; S Fica, Elias Hospital, Bucharest, Romania; R García-
23 Centeno, Hospital General Universitario Gregorio Marañón, Madrid, Spain; E Ghigo,
24 Molinette Hospital, Department of Internal Medicine, Turin, Italy; M Goth, Division of

1 Endocrinology, 2nd Department of Medicine, State Health Center, Budapest, Hungary; M
2 Godlewska, Department of Endocrinology, Jagiellonian University, Medical College,
3 Krakow, Poland; Y Greenman, Institute of Endocrinology, Metabolism and hypertension, Tel
4 Aviv, Israel; I Halperin, Department of Endocrinology, Hospital Clinic Barcelona, IDIBAPS,
5 UB, Barcelona, Spain; FA Hanzu, Department of Endocrinology, Hospital Clinic Barcelona,
6 IDIBAPS, UB, Barcelona, Spain; A Hermus, Radboud University Medical Center, Nijmegen
7 The Netherlands; G Johannsson, Goteborg University, Goteborg, Sweden; E Hubina,
8 Division of Endocrinology, 2nd Department of Medicine, State Health Center, Budapest,
9 Hungary; A Januszewska, Department of Endocrinology, Jagiellonian University, Medical
10 College, Krakow, P Kamenicky, Univ Paris-Sud, Université Paris-Saclay UMR-S1185, Le
11 Kremlin Bicêtre, Paris F-94276, France, Assistance Publique-Hôpitaux de Paris, Hôpital de
12 Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bicêtre,
13 Paris, F-94275, Institut National de la Santé et de la Recherche Médicale U1185, Le Kremlin
14 Bicêtre, Paris F-94276, France; A Kasperlik-Zaluska, Centre for Postgraduate Medical
15 Education, Warsaw, Poland; J Kirchner, Division of Clinical Endocrinology, Department of
16 Medicine CCM, Charité-Universitätsmedizin, Berlin, Germany; D Kastelan, Department of
17 Endocrinology, University Hospital Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia; I
18 Komerdus, Moscow Regional Research Clinical Institute n.a. Vladimirsky, Moscow, Russia;
19 I Kraljevic, Department of Endocrinology, University Hospital Zagreb, Kispaticeva 12,
20 10000 Zagreb, Croatia; M Krsek, 2nd Department of Medicine 3rd Faculty of Medicine,
21 Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic;
22 A Kruszynska, Centre for Postgraduate Medical Education, Warsaw, , Albacete, Spain; C
23 Lamas, Complejo Hospitalario Universitario de Albacete; I Lambrescu, Elias Hospital,
24 Bucharest, Romania; S Lang, Max-Planck-Gesellschaft zur Forderung der Wissenschaften

1 e.V., Munich, Germany; A Luger, Medizinische Universität Wien, Wien, Austria; D Maiter,
2 UCL Cliniques Universitaires St Luc, Brussels, Belgium; N Marpole, Christie Hospital, NHS
3 Trust, Manchester, UK; S Martin, Elias Hospital, Bucharest, Romania; M Martinie, Service
4 d'Endocrinologie-Diabétologie-Nutrition, Grenoble Cedex, France; MJ Martins Oliveira,
5 Centro Hospitalar Vila Nova Gaia /Espinho; O Moros, Zentrum für Endokrinologie,
6 Diabetologie, Rheumatologie Dr Demtröder & Kollegen im MVZ Dr. Eberhard & Partner
7 und Klinikum Dortmund; R Netea-Maier, Radboud University Nijmegen Medical Centre,
8 Nijmegen, The Netherlands; J Newell-Price, The University of Sheffield, Sheffield, UK; M
9 Orbetzova, Clinic of Endocrinology and Metabolic Diseases, "Sv.Georgy" University
10 Hospital, Medical University, Plovdiv, Bulgaria; I Paiva, Hospitais da Universidade de
11 Coimbra; F Pecori Giraldi, Istituto Auxologico Italiano IRCCS, University of Milan, Italy;
12 JC Percovich, Hospital General Universitario Gregorio Marañón; AM Pereira, Leiden
13 University Medical Center, Leiden, The Netherlands; M Pfeifer, Klinični Center, Ljubljana,
14 Slovenia; J Pickel, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.,
15 Munich, Germany; V Pirags, Pauls Stradiņš Clinical University Hospital, University of
16 Latvia, Riga, Latvia; O Ragnarsson, Goteborg University, Goteborg, Sweden; AD Reghina,
17 Elias Hospital, Bucharest, Romania; M Reincke, Medizinische Klinik und Poliklinik IV,
18 Campus Innenstadt, Klinikum der Universität München, Ludwig-Maximilians-Universität
19 München, Munich, Germany; P Riesgo, Neurosurgery Department, Hospital Universitario
20 de la Ribera, Alzira, Spain; M Roberts, Christie Hospital, NHS Trust, Manchester, UK; S
21 Roerink, Radboud University Medical Center, Nijmegen The Netherlands; O Roig, IIB-Sant
22 Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de
23 Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII;
24 C Rowan, Christie Hospital, NHS Trust, Manchester, UK; P Rudenko, Estonian Endocrine

1 Society, Tallinn, Estonia; MA Sahnoun, Aix-Marseille Université, CNRS, CRN2M UMR
2 7286, 13344 cedex 15, Marseille, and APHM, Hôpital Conception, Marseille, France; J
3 Salvador, University of Navarra, Pamplona, Spain; A Santos, IIB-Sant Pau, Department of
4 Endocrinology/Medicine, Hospital Sant Pau, UAB, Centro de Investigación Biomédica en
5 Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain; C Scaroni,
6 Endocrinology Unit, University-Hospital of Padova; HA Sigurjonsdottir, Landspítali
7 University Hospital, Reykjavik, Iceland and Faculty of Medicine, University of Iceland,
8 Reykjavik, Iceland; T Skoric Polovina, Department of Endocrinology, University Hospital
9 Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia; R Smith, Oxford Radcliffe Hospitals NHS
10 Trust, Oxford, UK; B Stachowska, Department of Endocrinology, Diabetology and Isotope
11 Therapy Wroclaw Medical University, Wroclaw, Poland; G Stalla, Max-Planck-
12 Gesellschaft zur Forderung der Wissenschaften e.V., Munich, Germany; C Strasburger,
13 Division of Clinical Endocrinology, Department of Medicine CCM, Charité-
14 Universitätsmedizin, Berlin, Germany ; A Tabarin, Department of Endocrinology, Diabetes
15 and Nutrition, University of Bordeaux, Bordeaux, France; M Terzolo, Internal Medicine –
16 Endocrinology, San Luigi Hospital; J Töke, 2nd Department of Medicine, Semmelweis
17 University, Budapest, Hungary; M Tóth, 2nd Department of Medicine, Semmelweis
18 University, Budapest, Hungary; P Touraine, GH Pitie Salpetriere - Dep. of endocrinology
19 and repr. med.; PJ Trainer, Department of Endocrinology, Christie Hospital, Manchester,
20 UK; S Tsagarakis, Athens Polyclinic General Hospital & Evangelismos Hospital, Athens,
21 Greece; E Valassi, IIB-Sant Pau, Department of Endocrinology/Medicine, Hospital Sant Pau,
22 UAB, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER,
23 Unidad 747), ISCIII, Barcelona, Spain, Universitat Internacional de Catalunya (UIC); G Vila,
24 Medizinische Universitat Wien, Wien, Austria; S Vinay, Christie Hospital, NHS Trust,

1 Manchester, UK; M Wagenmakers, Radboud University Medical Center, Nijmegen The
2 Netherlands; S Webb, IIB-Sant Pau, Department of Endocrinology/Medicine, Hospital Sant
3 Pau, UAB, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER,
4 Unidad 747), ISCIII, Barcelona, Spain; S Werner, Praxis für Endokrinologie Droste,
5 Oldenburg, Germany; J Young, Univ Paris-Sud, Université Paris-Saclay UMR-S1185, Le
6 Kremlin Bicêtre, Paris F-94276, France, Assistance Publique-Hôpitaux de Paris, Hôpital de
7 Bicêtre, Service de Endocrinologie et des Maladies de la Reproduction, Le Kremlin Bicêtre,
8 Paris, F-94275, Institut National de la Santé et de la Recherche Médicale U1185, Le Kremlin
9 Bicêtre, Paris F-94276, France; P Zdunowski, Centre for Postgraduate Medical Education,
10 Warsaw, Poland; S Zacharieva, Medical University of Sofia, Sofia, Bulgaria ; K Zopf,
11 Division of Clinical Endocrinology, Department of Medicine CCM, Charité-
12 Universitätsmedizin, Berlin, Germany; S Zopp, Medizinische Klinik und Poliklinik IV,
13 Campus Innestadt, Klinikum der Universität München, München, Germany; I Zosin,
14 Romanian Society for Endocrinology, Timisoara, Romania.

15 Illustration: We thank Elsa Forneris for the design of Figure 1.

16

17

1 REFERENCES

2

- 3 1. Newell-Price J, Bertagna X, Grossman AB, & Nieman LK. Cushing's syndrome.
4 *Lancet (London, England)* 2006 **367** 1605–1617. (doi:10.1016/S0140-
5 6736(06)68699-6)
- 6 2. Pivonello R, Isidori AM, Martino MC De, Newell-Price J, Biller BMK, & Colao A.
7 Complications of Cushing's syndrome: state of the art. *The lancet. Diabetes &*
8 *endocrinology* 2016 **4** 611–629. (doi:10.1016/S2213-8587(16)00086-3)
- 9 3. Lacroix A, Feelders RA, Stratakis CA, & Nieman LK. Cushing's syndrome. *Lancet*
10 *(London, England)* 2015 **386** 913–927. (doi:10.1016/S0140-6736(14)61375-1)
- 11 4. Valassi E, Santos A, Yaneva M, Tóth M, Strasburger CJ, Chanson P, Wass JAH,
12 Chabre O, Pfeifer M, Feelders RA, Tsagarakis S, Trainer PJ, Franz H, Zopf K,
13 Zacharieva S, Lamberts SW, Tabarin A, & Webb SM. The European Registry on
14 Cushing's syndrome: 2-year experience. Baseline demographic and clinical
15 characteristics. *European journal of endocrinology* 2011 **165** 383–392.
16 (doi:10.1530/EJE-11-0272)
- 17 5. Abbafati C, Machado DB, Cislighi B, Salman OM, Karanikolos M, McKee M,
18 Abbas KM, Brady OJ, Larson HJ, Trias-Llimós S, Cummins S, Langan SM,
19 Sartorius B, Hafiz A, Jenabi E, Mohammad Gholi Mezerji N, Borzouei S, Azarian
20 G, Khazaei S, Abbasi M, Asghari B, Masoumi S, Komaki H, Taherkhani A, Adabi
21 M, Abbasifard M, Bazmandegan G, Kamiab Z, Vakilian A, ... Zhu C. Global age-
22 sex-specific fertility, mortality, healthy life expectancy (HALE), and population

- 1 estimates in 204 countries and territories, 1950-2019: a comprehensive demographic
2 analysis for the Global Burden of Disease Study 2019. *Lancet (London, England)*
3 2020 **396** 1160–1203. (doi:10.1016/S0140-6736(20)30977-6)
- 4 6. Lambert JK, Goldberg L, Fayngold S, Kostadinov J, Post KD, & Geer EB.
5 Predictors of mortality and long-term outcomes in treated Cushing’s disease: a study
6 of 346 patients. *The Journal of clinical endocrinology and metabolism* 2013 **98**
7 1022–1030. (doi:10.1210/JC.2012-2893)
- 8 7. Valassi E, Tabarin A, Brue T, Feelders RA, Reincke M, Netea-Maier R, Tóth M,
9 Zacharieva S, Webb SM, Tsagarakis S, Chanson P, Pfeiffer M, Droste M, Komerdus
10 I, Kastelan D, Maiter D, Chabre O, Franz H, Santos A, Strasburger CJ, Trainer PJ,
11 Newell-Price J, Ragnarsson O High mortality within 90 days of diagnosis in patients
12 with Cushing’s syndrome: results from the ERCUSYN registry. *European journal of*
13 *endocrinology* 2019 **181** 461–472. (doi:10.1530/EJE-19-0464)
- 14 8. Valassi E, Feelders R, Maiter D, Chanson P, Yaneva M, Reincke M, Krsek M, Tóth
15 M, Webb SM, Santos A, Paiva I, Komerdus I, Droste M, Tabarin A, Strasburger CJ,
16 Franz H, Trainer PJ, Newell-Price J, Wass JAH, Papakokkinou E, Ragnarsson
17 O Worse Health-Related Quality of Life at long-term follow-up in patients with
18 Cushing’s disease than patients with cortisol producing adenoma. Data from the
19 ERCUSYN. *Clinical endocrinology* 2018 **88** 787–798. (doi:10.1111/CEN.13600)
- 20 9. Tsubota A, Shishiba Y, Shimizu T, Ozawa Y, Sawano S, & Yamada S. Masked
21 Cushing’s disease in an aged man associated with intraventricular hemorrhage and
22 tuberculous peritonitis. *Japanese journal of medicine* 1991 **30** 233–237.

- 1 (doi:10.2169/INTERNALMEDICINE1962.30.233)
- 2 10. Donckier J, Burrin JM, Ramsay ID, & Joplin GF. Successful control of Cushing's
3 disease in the elderly with long term metyrapone. *Postgraduate medical journal*
4 1986 **62** 727–730. (doi:10.1136/PGMJ.62.730.727)
- 5 11. Haraguchi Y, Mizoguchi Y, Noguchi T, Arai T, Fukuyama J, Kato TA, Kawashima
6 T, & Monji A. A patient with Alzheimer's disease complicated by elderly-onset
7 Cushing's syndrome who had undergone surgical treatment for adrenocorticotrophic
8 hormone-independent macronodular adrenal hyperplasia. *Psychogeriatrics : the*
9 *official journal of the Japanese Psychogeriatric Society* 2016 **16** 274–276.
10 (doi:10.1111/PSYG.12146)
- 11 12. Berwaerts JJ, Verhelst JA, Verhaert GC, Verhaegen AA, & Abs RE. Corticotropin-
12 dependent Cushing's syndrome in older people: presentation of five cases and
13 therapeutical use of ketoconazole. *Journal of the American Geriatrics Society* 1998
14 **46** 880–884. (doi:10.1111/J.1532-5415.1998.TB02723.X)
- 15 13. Minniti G, Esposito V, Piccirilli M, Fratticci A, Santoro A, & Jaffrain-Rea ML.
16 Diagnosis and management of pituitary tumours in the elderly: a review based on
17 personal experience and evidence of literature. *European journal of endocrinology*
18 2005 **153** 723–735. (doi:10.1530/EJE.1.02030)
- 19 14. Qiao N, Swearingen B, & Tritos NA. Cushing's disease in older patients:
20 Presentation and outcome. *Clinical endocrinology* 2018 **89** 444–453.
21 (doi:10.1111/CEN.13799)
- 22 15. Hosoi T & Sawabe M. Reviewing the definition of 'elderly'. *Article in Geriatrics*

- 1 *and Gerontology International* 2006 . (doi:10.1111/j.1447-0594.2006.00341.x)
- 2 16. Broder MS, Neary MP, Chang E, Cherepanov D, & Ludlam WH. Incidence of
3 Cushing's syndrome and Cushing's disease in commercially-insured patients.
4 *Pituitary* 2015 **18** 283–289. (doi:10.1007/S11102-014-0569-6)
- 5 17. Giraldi FP, Cassarino MF, Sesta A, Terreni M, Lasio G, & Losa M. Sexual
6 Dimorphism in Cellular and Molecular Features in Human ACTH-Secreting
7 Pituitary Adenomas. *Cancers* 2020, Vol. 12, Page 669 2020 **12** 669.
8 (doi:10.3390/CANCERS12030669)
- 9 18. Chaidarun SS, Swearingen B, & Alexander JM. Differential expression of estrogen
10 receptor-beta (ER beta) in human pituitary tumors: functional interactions with ER
11 alpha and a tumor-specific splice variant. *The Journal of clinical endocrinology and*
12 *metabolism* 1998 **83** 3308–3315. (doi:10.1210/JCEM.83.9.5128)
- 13 19. Storr HL, Isidori AM, Monson JP, Besser GM, Grossman AB, & Savage MO.
14 Prepubertal Cushing's disease is more common in males, but there is no increase in
15 severity at diagnosis. *The Journal of clinical endocrinology and metabolism* 2004 **89**
16 3818–3820. (doi:10.1210/JC.2003-031531)
- 17 20. Alexopoulos GS. Depression in the elderly. *Lancet (London, England)* 2005 **365**
18 1961–1970. (doi:10.1016/S0140-6736(05)66665-2)
- 19 21. Hegeman JM, Waal MWM De, Comijs HC, Kok RM, & Mast RC Van Der.
20 Depression in later life: A more somatic presentation? *Journal of Affective Disorders*
21 2015 **170** 196–202. (doi:10.1016/J.JAD.2014.08.032)
- 22 22. Valassi E, Chiodini I, Feelders RA, Andela CD, Abou-Hanna M, Idres S, & Tabarin

- 1 A. Unmet needs in Cushing's syndrome: the patients' perspective. *Endocrine*
2 *connections* 2022 **11** . (doi:10.1530/EC-22-0027)
- 3 23. Ford BC, Bullard KMK, Taylor RJ, Toler AK, Neighbors HW, & Jackson JS.
4 Lifetime and 12-month prevalence of diagnostic and statistical manual of mental
5 disorders, fourth edition disorders among older african americans: Findings from the
6 national survey of American life. *American Journal of Geriatric Psychiatry* 2007 **15**
7 652–659. (doi:10.1097/JGP.0b013e3180437d9e)
- 8 24. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C,
9 Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E,
10 Vandewoude M, Visser M, & Zamboni M. Sarcopenia: revised European consensus
11 on definition and diagnosis. *Age and ageing* 2019 **48** 601.
12 (doi:10.1093/AGEING/AFZ046)
- 13 25. Martel-Duguech L, Alonso-Jimenez A, Bascuñana H, Díaz-Manera J, Llauger J,
14 Nuñez-Peralta C, Montesinos P, Webb SM, & Valassi E. Prevalence of sarcopenia
15 after remission of hypercortisolism and its impact on HRQoL. *Clinical*
16 *endocrinology* 2021 **95** 735–743. (doi:10.1111/CEN.14568)
- 17 26. Vogel F, Braun LT, Rubinstein G, Zopp S, Künzel H, Strasding F, Albani A, Riester
18 A, Schmidmaier R, Bidlingmaier M, Quinkler M, Deutschbein T, Beuschlein F, &
19 Reincke M. Persisting Muscle Dysfunction in Cushing's Syndrome Despite
20 Biochemical Remission. *The Journal of clinical endocrinology and metabolism* 2020
21 **105** . (doi:10.1210/CLINEM/DGAA625)
- 22 27. Rossum EFC Van, Voorhoeve PG, Velde SJ Te, Koper JW, Delemarre-Van De Waal

- 1 HA, Kemper HCG, & Lamberts SWJ. The ER22/23EK polymorphism in the
2 glucocorticoid receptor gene is associated with a beneficial body composition and
3 muscle strength in young adults. *The Journal of clinical endocrinology and*
4 *metabolism* 2004 **89** 4004–4009. (doi:10.1210/JC.2003-031422)
- 5 28. Fernandez-Rodriguez E, Stewart PM, & Cooper MS. The pituitary-adrenal axis and
6 body composition. *Pituitary* 2009 **12** 105–115. (doi:10.1007/S11102-008-0098-2)
- 7 29. Agba OB, Lausser L, Huse K, Bergmeier C, Jahn N, Groth M, Bens M, Sahm A, Gall
8 M, Witte OW et al. Tissue-, sex-, and age-specific DNA methylation of rat
9 glucocorticoid receptor gene promoter and insulin-like growth factor 2 imprinting
10 control region. *Physiol Genom* 2017 **49**:609-702 doi:
11 10.1152/physiolgenomics.00009.2017.
- 12 30. Vogel F, Braun L, Rubinstein G, Zopp S, Benedix S, Schneider H, Ritzel K,
13 Schilbach K, Schmidmaier R, Beuschlein F, Bidlingmaier M, & Reincke M. Patients
14 with low IGF-I after curative surgery for Cushing's syndrome have an adverse long-
15 term outcome of hypercortisolism-induced myopathy. *European journal of*
16 *endocrinology* 2021 **184** 813–821. (doi:10.1530/EJE-20-1285)
- 17 31. Travison TG, Morley JE, Araujo AB, O'Donnell AB, & McKinlay JB. The
18 relationship between libido and testosterone levels in aging men. *The Journal of*
19 *clinical endocrinology and metabolism* 2006 **91** 2509–2513. (doi:10.1210/JC.2005-
20 2508)
- 21 32. Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO,
22 Tabarin A, & Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine

- 1 Society Clinical Practice Guideline. *The Journal of clinical endocrinology and*
2 *metabolism* 2015 **100** 2807–2831. (doi:10.1210/jc.2015-1818)
- 3 33. Thakur JD, Corlin A, Mallari RJ, Yawitz S, Eisenberg A, Sivakumar W, Griffiths C,
4 Carrau RL, Rettinger S, Cohan P, Krauss H, Araque KA, Barkhoudarian G, & Kelly
5 DF. Complication avoidance protocols in endoscopic pituitary adenoma surgery: a
6 retrospective cohort study in 514 patients. *Pituitary* 2021 **24** 930–942.
7 (doi:10.1007/S11102-021-01167-Y)
- 8 34. Clayton RN, Raskauskiene D, Reulen RC, & Jones PW. Mortality and morbidity in
9 Cushing’s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of
10 literature. *The Journal of clinical endocrinology and metabolism* 2011 **96** 632–642.
11 (doi:10.1210/JC.2010-1942)
- 12 35. Ragnarsson O, Olsson DS, Papakokkinou E, Chantzichristos D, Dahlqvist P,
13 Segerstedt E, Olsson T, Petersson M, Berinder K, Bensing S, Hoybye C, Eden-
14 Engstrom B, Burman P, Bonelli L, Follin C, Petranek D, Erfurth EM, Wahlberg J,
15 Ekman B, Åkerman AK, Schwarcz E, Bryngelsson IL, & Johannsson G. Overall and
16 Disease-Specific Mortality in Patients With Cushing Disease: A Swedish
17 Nationwide Study. *The Journal of clinical endocrinology and metabolism* 2019 **104**
18 2375–2384. (doi:10.1210/JC.2018-02524)

19

20

1 **LEGENDS**

2 **Figure 1.** Common clinical presentation of patients with PIT-CS, depending on age. [This](#)
3 [picture represents some age-related differences in clinical presentation. A detailed](#)
4 [description of all the features found is provided in the text](#)

5 **Figure 2.** Disease free survival of younger and older patients after successful
6 transsphenoidal surgery (Kaplan-Meier analysis).

7 **Table 1.** Comparison of clinical presentations at diagnosis in elderly patients (≥ 65 years
8 old) with CS versus younger patients (< 65 years old) with CS.

9 **Table 2.** Comparison of clinical presentations at diagnosis in elderly patients (≥ 65 years
10 old) with PIT-CS versus younger patients (< 65 years old) with PIT-CS.

11 **Table 3.** Comparison of clinical presentations at diagnosis in elderly patients (≥ 65 years
12 old) with ADR-CS versus younger patients (< 65 years old) with ADR-CS.

13 **Table 4.** Comparison of clinical presentations at diagnosis in elderly patients (≥ 65 years
14 old) with CS versus younger patients (< 65 years old) with CS, depending on age.

15 p value^a: Comparison of initial clinical presentation between males and females among
16 younger patients (< 65 years old) with CS.

17 p value^b: Comparison of initial clinical presentation between males and females among
18 older patients (≥ 65 years old) with CS.

19 **Table 5.** Comparison of management strategies in elderly patients (≥ 65 years old) with
20 PIT-CS versus younger patients (< 65 years old) with PIT-CS.

21

	< 65 years old	≥ 65 years old	p value
Number of patients, n(%)	1616 (90.2)	175 (9.8)	-
PIT-CS, n(%)	1131 (70)	103 (58.8)	<0.01
ADR-CS, n(%)	398 (24.6)	52 (29.7)	0.1
ECT-CS, n(%)	87 (5.4)	20 (11.5)	<0.01
Age (year), mean+/-SD	42+/-12	69.6+/-4.7	<0.01
Female, n(%)	1289 (79.7)	107 (61.1)	<0.01
Onset of symptoms (year), mean+/-SD	2.9+/-3.3	3.1+/-4.8	0.5
ON DEX cortisol (nmol/L), mean+/-SD	496+/-375	436+/-317	0.3
BMI, mean+/-SD	29.7+/-7.1	26.7+/-5.7	<0.01
Waist circumference (cm), mean+/-SD	103.1+/-16.5	97.1+/- 10.8	<0.01
Hypertension, n(%)	1084 (67.1)	156 (89.1)	<0.01
SBP (mmHg), mean+/-SD	140+/-21	149+/-22	<0.01
DBP (mmHg), mean+/-SD	88+/-14	84+/-12	<0.01
Muscle weakness, n(%)	821 (50.9)	101 (57.7)	0.09
Diabetes mellitus, n(%)	446 (27.6)	84 (48)	<0.01
Depression, n(%)	538 (33.3)	35 (20)	<0.01
Loss of libido, n(%)	325 (20.1)	14 (8)	<0.01
Hair loss (only for females), n(%)	351 (27.2)	22 (20.7)	0.03
Hirsutism (only for females), n(%)	668 (51.8)	23 (21.5)	<0.01
Skin symptoms, n(%)	1123 (69.4)	103 (58.8)	<0.01
Weight gain, n(%)	1184 (73.2)	87 (49.7)	<0.01
Fractures, n(%)	217 (13.4)	38 (21.7)	<0.01

Followed by a psychiatrist, n(%)	170 (10.5)	9 (5.1)	0.02
-------------------------------------	------------	---------	-------------

Table 1. Comparison of clinical presentations at diagnosis in elderly patients (≥ 65 years old) with CS versus younger patients (< 65 years old) with CS.

	< 65 years old	≥ 65 years old	p value
Number of patients, n(%)	1131 (91.7)	103 (8.3)	-
Age (year), mean \pm -SD	40.9 \pm -12.2	70.2 \pm -4.7	<0.01
Female, n(%)	889 (72)	56 (54.3)	<0.01
Onset of symptoms (year), mean \pm -SD	3 \pm -3.2	2.6 \pm -3.6	0.5
UFC/24h, mean \pm -SD	898 \pm -1219	900 \pm -899	0.6
ON DEX cortisol (nmol/L), mean \pm -SD	496 \pm -375	436 \pm -317	0.3
BMI, mean \pm -SD	29.7 \pm -20.6	24.2 \pm -12.7	<0.01
Waist circumference (cm), mean \pm -SD	103.9 \pm -16.7	95 \pm - 10.4	<0.01
Hypertension, n(%)	724 (64)	93 (90.2)	<0.01
SBP (mmHg), mean \pm -SD	138 \pm -20.2	149 \pm -22	<0.01
DBP (mmHg), mean \pm -SD	87 \pm -13.7	86 \pm -14.1	0.7
Muscle weakness, n(%)	551 (48.7)	61 (59.2)	0.04
Diabetes mellitus, n(%)	307 (23.1)	42 (40.7)	<0.01
Depression, n(%)	394 (34.8)	19 (18.4)	<0.01
Loss of libido, n(%)	241 (21.3)	5 (4.8)	<0.01
Hair loss (only for females), n(%)	242 (27.2)	13 (26.5)	0.2
Hirsutism (only for females), n(%)	524 (58.9)	13 (26.5)	<0.01
Skin symptoms, n(%)	818 (72.3)	67 (65)	0.1
Weight gain, n(%)	904 (79.9)	53 (51.4)	<0.01
Fractures, n(%)	154 (13.6)	26 (25.2)	<0.01
Followed by a psychiatrist, n(%)	119 (10.5)	4 (3.8)	0.03

Table 2. Comparison of clinical presentations at diagnosis in elderly patients (≥ 65 years old) with PIT-CS versus younger patients (< 65 years old) with PIT-CS.

	< 65 years old	≥ 65 years old	p value
Number of patients, n(%)	398 (88.4)	52 (11.6)	-
Age (year), mean+/-SD	44.6+/-11.3	67.8+/-3.1	<0.01
Female, n(%)	352 (88.4)	38 (73.1)	<0.01
Onset of symptoms (year), mean+/-SD	2.7+/-3.5	3.7+/-5.3	0.9
BMI, mean+/-SD	29.9+/-6.7	30.2+/-5.4	0.5
Waist circumference (cm), mean+/-SD	102.4+/-16.6	103.4+/-11.8	0.5
Hypertension, n(%)	291 (73.1)	45 (86.5)	0.03
SBP (mmHg), mean+/-SD	142+/-19	144+/-20	0.7
DBP (mmHg), mean+/-SD	89+/-13	82+/-8	0.3
Muscle weakness, n(%)	202 (50.7)	24 (46.1)	0.5
Diabetes mellitus, n(%)	112 (28.1)	26 (50)	<0.01
Depression, n(%)	118 (29.6)	10 (19.2)	0.5
Loss of libido, n(%)	67 (16.8)	6 (11.5)	0.4
Hair loss (only for females), n(%)	97 (27.5)	6 (17.1)	0.03
Hirsutism (only for females), n(%)	116 (32.9)	8 (21)	0.02
Skin symptoms, n(%)	238 (59.7)	23 (44.2)	0.03
Weight gain, n(%)	226 (56.7)	26 (50)	0.3
Fractures, n(%)	49 (12.3)	9 (17.3)	0.3
Followed by a psychiatrist, n(%)	46 (11.5)	4 (7.7)	0.5

1
2
3
4
5
6

Table 3. Comparison of clinical presentations at diagnosis in elderly patients (≥65 years old) with ADR-CS versus younger patients (<65 years old) with ADR-CS.

	< 65 years old FEMALES	< 65 years old MALES	≥ 65 years old FEMALES	≥ 65 years old MALES	p value ^a	p value ^b
Number of patients, n(%)	1291	325	107	68	-	-
Age (year), mean±SD	42±11	42±12	68±4	69±4	0.9	0,8
Onset of symptoms (year), mean±SD	2±2	2±2	3±4	2±5	0.7	0.07
BMI, mean+/-SD	28±16.4	29.6±6	26.8±8.8	26±9*	0.1	0.8
Waist circumference (cm), mean±SD	102±17	105±11	96±10	97±10	0.09	0.6
Weight gain, n(%)	1019 (79)	252 (78)	56 (53)**	34 (50)	0.5	0.7
Muscle weakness, n(%)	615 (48)	206 (63)	63 (59)**	41 (60)	<0,01	0.8
SBP (mmHg), mean+/-SD	139±21	147±20	152±15	140±6	<0,01	<0.01
DBP (mmHg), mean+/-SD	87±13	91±15	83±20	84±11	0,02	0.7
Hypertension, n(%)	830 (64)	254 (78)	96 (90)**	60 (88)	<0.01	0.7
Diabetes mellitus, n(%)	354 (27)	112 (34)	56 (52)**	36 (53)*	0.01	0.9
Fractures, n(%)	145 (11)	81 (25)	26 (24)**	13 (19)	<0.01	0.4
Depression, n(%)	408 (32)	130 (40)	23 (22)**	9 (19)*	<0.01	0.2
Loss of libido, n(%)	214 (17)	112 (35)	4 (4)	14 (21)	<0.01	<0.01

Table 4. Comparison of clinical presentations at diagnosis in older (≥65 years old) versus younger (<65 years old) CS patients, depending on gender.

p value^a: Male vs. female younger patients

p value^b: Male vs. female older patients

*p<0.05 vs. younger male patients

**p<0.05 vs. younger female patients

1


	<65 years old	≥65 years old	p value
No pituitary surgery, n(%)	120 (10)	32 (31)	<0.01
1 pituitary surgery, n(%)	804 (71)	60 (58)	<0.01
2 or more pituitary surgeries, n(%)	207 (18)	11 (10)	0.05
Medical therapy as first line, n(%)	307 (27)	41 (39)	<0.01
Bilateral adrenalectomy, n(%)	56 (4)	5 (4)	1
RT, n(%)	120 (10)	17 (13)	0.06
RT as first line therapy, n(%)	8 (7)	6 (35)	<0.01
RT as second line therapy, (%)	112 (93)	11 (65)	<0.01

2

3

4 **Table 5. Comparison of management strategies in elderly patients (≥65 years old) with**
5 **PIT- CS versus younger patients (<65 years old) with PIT-CS.**

6



7 **Figure 1 - Common clinical presentation of patients with CD, depending on age**


7

8

9

Figure 1
210x148 mm (x DPI)

Figure 2. Disease free survival of younger and older patients after successful transsphenoidal surgery.



1
2
3

Figure 2
559x314 mm (x DPI)

ACCEPTED MANUSCRIPT